<DOC>
	<DOCNO>NCT00362674</DOCNO>
	<brief_summary>The purpose study evaluate durability antiviral activity chronic hepatitis B patient show complete response L-FMAU-301 , L-FMAU-302 L-FMAU-303 trial .</brief_summary>
	<brief_title>Durability Antiviral Activity Chronic HBV Patients Who Showed Complete Response L-FMAU-301,302 303 Trial</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . The patient complete LFMAU301 , LFMAU302 LFMAU303 . 2 . Patients show complete response ( ALT normalization HBV DNA &lt; 4,700 copies/mL LFMAU301 LFMAU302 , addition , HBeAg seroconverted antiHBe last two visit LFMAU301 ) completion LFMAU301 LFMAU302 treat clevudine . 3 . Patients show complete response ( ALT normalization HBV DNA &lt; 4,700 copies/mL , addition HBeAg seroconverted antiHBe last two visit show HBeAg positiv baseline ) completion LFMAU303 4 . Patients able give write informed consent prior study start comply study requirement . 5 . Patients bilirubin level less 2.0 mg/dL , prothrombin time le 1.7 ( INR ) , serum albumin level least 3.5 g/dL last visit LFMAU301 , LFMAU302 LFMAU303 . 1 . Patients show complete response previously treat placebo LFMAU301 , LFMAU302 . 2 . Patients currently receive antiviral , immunomodulatory corticosteroid therapy . 3 . Patients previously treat interferon , lamivudine , lobucavir , famciclovir , adefovir investigational nucleoside HBV infection . 4 . Patients history ascites , variceal hemorrhage hepatic encephalopathy . 5 . Patients coinfected HCV , HDV HIV . 6 . Patients liver mass ( hemangioma , nodule ) , biliary disease except asymptomatic GB stone LFMAU301 , LFMAU302 LFMAU303 . 7 . Patients pregnant breastfeeding . 8 . Patients significant gastrointestinal , renal , hepatic ( decompensated ) , biliary disease except asymptomatic GB stone , bronchopulmonary , neurological , cardiovascular , oncologic allergic disease . The patient benign tumor exclude judged investigator continuation study would interfere benign tumor . 9 . Patients suitable study judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>